Stifel Financial Corp Cuts Stock Position in Kenvue Inc. (NYSE:KVUE)

Stifel Financial Corp lessened its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 16.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 802,778 shares of the company's stock after selling 155,457 shares during the quarter. Stifel Financial Corp's holdings in Kenvue were worth $17,139,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in KVUE. Grove Bank & Trust increased its position in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in Kenvue in the 4th quarter worth about $29,000. SRS Capital Advisors Inc. raised its stake in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after acquiring an additional 571 shares during the period. Fortitude Family Office LLC lifted its holdings in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc boosted its position in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after purchasing an additional 1,441 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently commented on KVUE. Piper Sandler raised their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. UBS Group cut their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Canaccord Genuity Group boosted their price objective on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Redburn Atlantic initiated coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price for the company. Finally, Barclays decreased their price target on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Monday, April 14th. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $24.42.

Kenvue Stock Performance

NYSE KVUE opened at $23.03 on Friday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a fifty day moving average of $23.03 and a 200-day moving average of $22.43. The company has a market capitalization of $44.19 billion, a P/E ratio of 43.45, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.56%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue's payout ratio is currently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.